Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer (NYSE:PFE) is preparing multiple presentations for the upcoming ASCO conference that spotlight new data across its ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer (NYSE:PFE) received U.S. FDA Priority Review for a supplemental Biologics License Application covering PADCEV plus ...

Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track. That kind of price decline doesn't happen by accident, which means you need to carefully ...

Track Pfizer share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, ...

--Currently down nine consecutive days; down 11.06% over this period --Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine ...

(PFE) is running a Phase 2 trial of ritlecitinib in adults with moderate to severe hidradenitis suppurativa, a chronic skin disease that causes painful lumps. The study, officially titled “A Phase 2, ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...